[8] As of 2020, he is leading the first research collaboration to explore return of genomic results and better understand penetrance in a population-based cohort of underrepresented minorities.

The study was a series of multi-site, randomized, controlled clinical trials that provide empirical data to address ethical, social and translational issues in genetic susceptibility testing for common diseases.

[18] Green also contributed to the design of a variant classification pipeline,[19] and a single page summary for reporting clinically relevant results of whole genome sequencing to physicians.

[27] He was previously co-chair of the steering committee of the NIH Consortium in Newborn Sequencing in Genomic Medicine and Public Health (NSIGHT).

[28] He served on the Institute of Medicine Committee on the "Evidence Base for Genetic Testing," and has collaborated on research studies with Illumina (company), 23andMe, Pathway and Google.